AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 02/26/21

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Amneal Pharmaceuticals (AMRX) shares rise nearly 5% premarket after posting fourth-quarter revenue that beat Wall Street estimates, helped by its AvKARE acquisition and new product launches.Net revenue in the fourth quarter of 2020 was $510M, an increase of 28% compared to $397M in the p...

Amneal Pharmaceuticals (AMRX) is surging with a ~6.3% gain in the pre-market today after its Q4 2020 earnings came ahead of analyst expectations.The company also announced the FDA approval for its Abbreviated New Drug Application ("ANDA") for Norelgestromin and Ethinyl Estradiol Tra...

Amneal Pharmaceuticals (AMRX): Q4 Non-GAAP EPS of $0.14 beats by $0.01; GAAP EPS of -$0.02 misses by $0.01.Revenue of $510.03M (+28.4% Y/Y) beats by $3.12M.Press Release For further details see: Amneal Pharmaceuticals EPS beats by $0.01, beats on revenue

‒ Q4 2020 Net Revenue of $510 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $0.02 ‒ ‒ Q4 2020 Adjusted Net Income (1) of $43 million; Adjusted EBITDA (1) of $107 million; Adjusted Diluted EPS (1) of $0.14 ‒ &#...

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q4 earnings results on Friday, February 26th, before market open.The consensus EPS Estimate is $0.13 (+62.5% Y/Y) and the consensus Revenue Estimate is $506.91M (+27.6% Y/Y).Over the last 2 years, AMRX has beaten EPS estimates 63% of...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences: Raymond James Institutional Investors Conference March 1, 2021 Fireside Chat – 3:00 p.m. Eastern Time...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2020 financial results on Friday, February 26, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this event. For further details see: Amneal Pharmaceuticlas (AMRX) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Amneal Pharmaceuticals (AMRX) announced that Amneal Pharmaceuticals LLC, a wholly-owned subsidiary of the company will be acquiring a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv BioSciences.Kashiv Specialty Pharmaceuticals is focused on the devel...